M. Fridkis-Hareli

发表

Bioinformatics-Based Predictions of Peptide Binding to Disease-Associated HLA Proteins Suggest Explanation for Shared Autoimmunity

P. Reche, J. Glutting, M. Fridkis-Hareli, 2011 .

Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis.

J. Granados, M. Fernandez-Vina, E. Yunis, 2010, Molecular immunology.

Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.

William Arbuthnot Sir Lane, J. Strominger, M. Sela, 1999, Journal of immunology.

Arthritis-Associated HLA-DR Molecules Sclerosis- and Rheumatoid Binding Motifs of Copolymer 1 to Multiple

William Arbuthnot Sir Lane, J. Strominger, M. Sela, 1999 .

Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

M. Fridkis-Hareli, J. Strominger, 1997, Journal of immunology.

Distribution Of Jewish And Non-Jewish Haplotypes Among Pemphigus Vulgaris Patients Worldwide

M. Fridkis-Hareli, 2006 .

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

M. Sela, R. Arnon, M. Fridkis-Hareli, 1996, Journal of Neuroimmunology.

Binding of random copolymers of three amino acids to class II MHC molecules.

J. Strominger, M. Sela, R. Arnon, 1999, International immunology.

Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.

L. Fugger, J. Strominger, Joel N.H. Stern, 2001, Human immunology.

Synthetic Copolymer I and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells

M. Sela, R. Arnon, M. Fridkis-Hareli, 1995 .

Development of Copolymer 1 (Copaxone®) as a Specific Drug Against Multiple Sclerosis

M. Sela, R. Arnon, R. Aharoni, 1999 .

Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells.

M. Sela, R. Arnon, M. Fridkis-Hareli, 1995, Cellular immunology.

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

M. Sela, R. Arnon, C. Brautbar, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Immune responses and vaccine development for cytomegalovirus infections.

M. Fridkis-Hareli, 2014 .

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease

M. Sela, A. Ben-nun, R. Arnon, 1996, Journal of Neurology.

The effect of linomide, an immunoregulator in experimental autoimmune diseases, on humoral antibody responses in mice.

I. Pecht, P. Falk, S. Slavin, 1997, Autoimmunity.

Differentiation patterns of CD4CD8 thymocyte subsets in cocultures of fetal thymus and lymphohemopoietic cells from c-fos transgenic and normal mice

A. Globerson, L. Eisenbach, M. Fridkis-Hareli, 1992 .

Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.

C. Brosnan, L. Fugger, J. Strominger, 2002, The Journal of clinical investigation.

Feedback regulation of T cell development in the thymus.

A. Perelson, A. Globerson, R. Mehr, 1996, Journal of theoretical biology.

Aging in the T Lymphocyte Compartment

A. Globerson, A. Sharp, R. Eren, 1992 .

Patterns of dual lymphocyte development in co-cultures of foetal thymus and lymphohaemopoietic cells from young and old mice.

A. Globerson, M. Fridkis-Hareli, L. Abel, 1992, Immunology.

Journal of Autoimmune Diseases BioMed Central Hypothesis

M. Fridkis-Hareli, 2008 .

Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease'?

R. Paus, M. Mahoney, M. Amagai, 2006, Experimental Dermatology.

Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.

D. Keskin, Joel N.H. Stern, M. Fridkis-Hareli, 2008, Cytokine.

Design of Peptide Immunotherapies for MHC Class-II-Associated Autoimmune Disorders

M. Fridkis-Hareli, 2013, Clinical & developmental immunology.

Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses.

L. Fugger, J. Strominger, M. Fridkis-Hareli, 2000, Human immunology.

Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

L. Fugger, J. Strominger, M. Fridkis-Hareli, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Interaction of KIR genes and G1M immunoglobulin allotypes confer susceptibility to type 2 diabetes in Puerto Rican Americans.

E. Yunis, J. Zúñiga, J. Pandey, 2006, Human immunology.

Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

D. Keskin, C. Brosnan, J. Strominger, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Influence of Ontogenic, Genetic and Environmental Factors

Z. Husain, E. Yunis, J. Zúñiga, 2008 .

Stem Cells in Aging: Influence of Ontogenic, Genetic and Environmental Factors.

Z. Husain, E. Yunis, J. Zúñiga, 2006, Journal of stem cells.

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.

L. Luzzatto, L. del Vecchio, A. Risitano, 2012, Blood.

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

A. Risitano, V. Holers, A. Lundberg, 2011, Blood.

Peptide-Based Immunotherapeutics and Vaccines

Darren R Flower, Pedro A Reche, D. Flower, 2014, Journal of immunology research.

The GP120 molecule of HIV-1 and its interaction with T cells.

J. Lee, D. Anastasiades, M. Fridkis-Hareli, 2010, Current medicinal chemistry.

Allele frequencies for 15 autosomal STR loci and admixture estimates in Puerto Rican Americans.

J. Granados, E. Yunis, J. Zúñiga, 2006, Forensic science international.

New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccination

E. Reinherz, M. Fridkis-Hareli, 2004, Medical Immunology.

Peptide Variants of Viral CTL Epitopes Mediate Positive Selection and Emigration of Ag-Specific Thymocytes In Vivo1

Ellis L Reinherz, Pedro A Reche, E. Reinherz, 2004, The Journal of Immunology.

Ag-Specific Thymocytes In Vivo Mediate Positive Selection and Emigration of Peptide Variants of Viral CTL Epitopes

E. Reinherz, P. Reche, M. Fridkis-Hareli, 2004 .

Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.

Derin B Keskin, D. Keskin, J. Strominger, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Peptide-Based Immunotherapeutics and Vaccines 2015

D. Flower, P. Reche, Y. Hoshino, 2015, Journal of immunology research.

Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells.

M. Sela, R. Arnon, I. Pecht, 1997, International immunology.

Differential expression of membrane polypeptides on fetal thymic stroma co-cultured with bone marrow cells from young and old mice

A. Globerson, M. Fridkis-Hareli, P. I. Francz, 1992, Mechanisms of Ageing and Development.

Regulatory feedback pathways in the thymus.

R Mehr, A S Perelson, M Fridkis-Hareli, 1997, Immunology today.

Feedback regulation of T cell development: manifestations in aging

Alan S. Perelson, Ramit Mehr, A. Perelson, 1996, Mechanisms of Ageing and Development.

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

K. Seyb, S. DeMarco, V. Rajagopal, 2015 .

complement-mediated hemolysis and C3 fragment paroxysmal nocturnal hemoglobinuria erythrocytes from The complement receptor 2/factor H fusion protein TT30 protects

L. Luzzatto, V. Holers, R. Notaro, 2012 .

The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models

A. Lundberg, S. Katti, N. Banda, 2019, Molecular immunology.

The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity

S. Katti, N. Banda, M. Fridkis-Hareli, 2012 .

MHC-linked colonization of the thymus and thymocyte development: effects of mature T lymphocytes.

A. Globerson, A. Sharp, R. Eren, 1995, International Archives of Allergy and Immunology.

Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease'?

R. Paus, M. Mahoney, M. Amagai, 2006, Experimental dermatology.

Thymocyte development in an in vitro constructed chimera of irradiated fetal thymus and lymphohemopoietic cells.

A. Globerson, A. Sharp, M. Fridkis-Hareli, 1991, Thymus.

Developmental interactions of CD4 T cells and thymocytes: age-related differential effects

A. Globerson, R. Mehr, M. Fridkis-Hareli, 1994, Mechanisms of Ageing and Development.

Immune Responses to CMV and Vaccine Development

M. Fridkis-Hareli, 2015 .

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

A. Risitano, M. Fridkis-Hareli, I. Mazsaroff, 2011, Blood.